--- title: "RegenETP, Inc. (RGTPQ.US)" type: "quote" locale: "en" url: "https://longbridge.com/en/quote/RGTPQ.US.md" symbol: "RGTPQ.US" name: "RegenETP, Inc." industry: "Biotechnology" --- # RegenETP, Inc. (RGTPQ.US) | Item | Detail | |------|--------| | Industry | Biotechnology | ## Company Profile RegenETP, Inc., a clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine Pro... ## Financial Score > *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.* > Updated: 2026-02-22T04:30:14.000Z **Overall: D (0.76)** **Industry**: Biotechnology | Metric | Value | |--------|-------| | Industry Ranking | 353 / 403 | | Industry Median | D | | Industry Average | C | - **Style**: Value - Stocks where the company's main business is in a mature stage. - **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns. ### Score Analysis **Style Score**: #### Growth Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | -98.66% | | | Net Profit YoY | 49.81% | | #### Value Score: | Indicator | Value | Rating | |-----------|-------|--------| | P/B Ratio | 0.00 | | | Dividend Ratio | 0.00% | | **Size Score**: #### Market Cap Score: | Indicator | Value | Rating | |-----------|-------|--------| | Market Cap | 0.00 | | #### Revenue Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue | 73000.00 | | **Multi Score**: D #### Profit Score: E | Indicator | Value | Rating | |-----------|-------|--------| | ROE | -54.97% | E | | Profit Margin | -11376.71% | E | | Gross Margin | 0.00% | E | #### Growth Score: E | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | -98.66% | E | | Net Profit YoY | 49.81% | B | | Total Assets YoY | -39.92% | E | | Net Assets YoY | -30.19% | E | #### Cash Score: E | Indicator | Value | Rating | |-----------|-------|--------| | Cash Flow Margin | -0.88% | D | | OCF YoY | -98.66% | E | #### Operating Score: E | Indicator | Value | Rating | |-----------|-------|--------| | Turnover | 0.00 | E | #### Debt Score: B | Indicator | Value | Rating | |-----------|-------|--------| | Gearing Ratio | 31.18% | B | ```chart-data:radar { "title": "Longbridge Financial Score - RegenETP, Inc.", "chart_type": "radar", "dimensions": [ { "name": "Profit", "grade": "E", "indicators": [ { "name": "ROE", "value": "-54.97%", "rating": "E" }, { "name": "Profit Margin", "value": "-11376.71%", "rating": "E" }, { "name": "Gross Margin", "value": "0.00%", "rating": "E" } ] }, { "name": "Growth", "grade": "E", "indicators": [ { "name": "Revenue YoY", "value": "-98.66%", "rating": "E" }, { "name": "Net Profit YoY", "value": "49.81%", "rating": "B" }, { "name": "Total Assets YoY", "value": "-39.92%", "rating": "E" }, { "name": "Net Assets YoY", "value": "-30.19%", "rating": "E" } ] }, { "name": "Cash", "grade": "E", "indicators": [ { "name": "Cash Flow Margin", "value": "-0.88%", "rating": "D" }, { "name": "OCF YoY", "value": "-98.66%", "rating": "E" } ] }, { "name": "Operating", "grade": "E", "indicators": [ { "name": "Turnover", "value": "0.00", "rating": "E" } ] }, { "name": "Security", "grade": "B", "indicators": [ { "name": "Gearing Ratio", "value": "31.18%", "rating": "B" } ] } ] } ``` ### Peer Comparison | Rank | Name | Profit | Growth | Operation | Security | Cash | Rating | |------|------|--------|--------|-----------|----------|------|--------| | 01 | Adma Biologics (US.ADMA) | A | A | A | B | B | A | | 02 | Kiniksa Pharmaceuticals (US.KNSA) | B | A | A | B | A | A | | 03 | Stoke Therapeutics (US.STOK) | A | A | B | A | B | A | | 04 | Rigel Pharma (US.RIGL) | A | A | A | C | B | A | | 05 | OpGen (US.OPGN) | B | A | A | A | B | A | ## Valuation Analysis | Metric | Current | Industry Ranking | High | Median | Low | |--------|---------|-----------------|------|--------|-----| | Dividend Yield | 0.00% | - | - | - | - | ## References - [Company Overview](https://longbridge.com/en/quote/RGTPQ.US/overview.md) - Shareholders, executives, business segments - [Financials](https://longbridge.com/en/quote/RGTPQ.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan - [Topics & Discussions](https://longbridge.com/en/quote/RGTPQ.US/topics.md) - Community topics and discussions --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.